Siffy

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Siffy

What is Siffy? Understanding its Origin and Purpose

Property Description
Active Ingredient Cefixime
Form Oral (Tablet, Capsule, Suspension)
Pharmacological Class Third-Generation Cephalosporin Antibiotic
Common Use Treating Bacterial Infections
Origin Semisynthetic

Siffy is a prescription-only medication primarily used to eliminate various types of bacterial infections throughout the body, such as infections of the ear, throat, and urinary tract. The drug's core function is to act as a broad-spectrum antibacterial agent, making it ineffective against illnesses caused by viruses. Siffy is a semisynthetic pharmaceutical agent, created in a laboratory from a naturally derived chemical precursor. Its primary purpose is to stop the progress of infection and restore health by attacking the infectious bacteria, a function clinically recognized for its reliability in short-course treatments.


Classifying Siffy: A Third-Generation Cephalosporin

Siffy belongs to the cephalosporin antibiotic family, which is part of the larger group of beta-lactam antibiotics, and is specifically categorized as a third-generation cephalosporin. This classification means its active component, Cefixime, is engineered to offer superior defense against many bacterial strains compared to older antibiotic generations. Cefixime works by interrupting the bacteria's ability to construct its protective outer layer, the cell wall, leading directly to the death of the bacterial cell. This mechanism is beneficial because the drug exhibits enhanced stability against bacterial defense mechanisms, such as certain beta-lactamase enzymes.


Composition and Available Forms of Cefixime

The core chemical component responsible for the antibacterial effect is the active ingredient Cefixime. Siffy is intended for oral administration and is manufactured in several dosage forms to accommodate patient needs. These forms include the standard tablet, the capsule, and the oral suspension, which is a liquid form often preferred for use in pediatric patients. While the drug is typically a single-active-ingredient product, specialized variants may be formulated as combination products—for instance, including Lactobacillus to support intestinal health or Sulbactam to address drug-resistant bacteria. The availability of Dispersible Tablet (DT) forms provides an essential point of differentiation, simplifying administration for patients who experience difficulty swallowing.

Regulatory References

  1. Cefixime Drug Information | MedlinePlus

What side effects are possible with Siffy?

Possible Side Effects and Safety Information

The safety profile of Siffy (Cefixime) is defined by officially documented adverse reactions classified by frequency and affected organ system. The most common effects documented in clinical trials are related to the Gastrointestinal System, primarily diarrhea, loose stools, nausea, abdominal pain, and vomiting. Most other adverse reactions occur with an incidence of less than 2%.


System-Organ Classes and Serious Adverse Reactions

Adverse effects are formally grouped into System-Organ Classes (SOC), including effects on the Hemic and Lymphatic System, Skin and Subcutaneous Tissue, and Hepatobiliary system (transient liver enzyme elevations).

Serious Adverse Reactions (SARs), though rare, are explicitly documented in regulatory labeling. These include potentially life-threatening Anaphylactic/Anaphylactoid Reactions and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Furthermore, the label notes the risk of Pseudomembranous Colitis, with symptoms that may appear during or up to two months after treatment cessation.


Safety Constraints and Population-Specific Notes

The medication is formally contraindicated for use in individuals with a known allergy to Cefixime or other cephalosporin antibiotics. Official safety statements emphasize that dose adjustment is required for patients with Renal Impairment (creatinine clearance < 60 mL/min), as failure to adjust the dose in this population may increase the risk of seizures. The safety and effectiveness of Siffy are not established in children aged less than six months.

Overdose and Emergency Response

Overdose and when to seek help

Siffy overdose is primarily characterized by anticipated gastrointestinal symptoms, including nausea, vomiting, and diarrhea. More critical manifestations involve the Central Nervous System, including a documented risk of neurotoxicity that can escalate to encephalopathy (presenting as confusion or impaired consciousness) and generalized seizures (convulsions).

Regulatory authorities note that patients with pre-existing renal impairment face an increased vulnerability to these severe neurological outcomes, as the drug is cleared less efficiently, leading to higher systemic exposure. The prescribing information explicitly requires drug discontinuation if seizures occur.

Management of an overdose is symptomatic and supportive, consistent with the official label statement that no specific antidote is known. Procedures such as hemodialysis or peritoneal dialysis are not effective for removing significant quantities of the drug from the bloodstream.

Immediate medical attention is required in the event of an overdose. You must contact emergency services immediately if critical signs are observed, such as an actual seizure, collapse, or sudden trouble breathing, as these indicate a severe, life-threatening scenario documented in official regulatory profiles.

Therapeutic Uses of Siffy

What Siffy Treats: Main Uses and Benefits

Siffy is commonly used to provide targeted symptomatic relief in situations where acute manifestations cause noticeable discomfort or functional strain. Its primary role is to ease the overall symptom burden, offering supportive management across several key clinical domains, and is considered relevant in contexts involving heightened systemic burden. Clinical care often involves such short-term assistance when symptoms are pronounced.

Therapeutic Domains and Patient Support

The therapeutic area of use includes conditions characterized by episodic or fluctuating symptom patterns and recurrent manifestations associated with increased discomfort or tension. Siffy is applied across domains where short-term symptom management is appropriate, especially when symptoms related to physical discomfort appear suddenly or intensify over time. The medication is relevant for managing symptoms that interfere with daily comfort and may be relevant when groups of symptoms create noticeable physiological strain.

Siffy supports day-to-day comfort, assists with maintaining functional stability when symptoms interfere with routine activities, and supports general well-being during symptomatic phases. Its application provides support that helps ease the overall symptom load during periods of heightened symptoms.


Quick Facts: Symptom Management

Siffy is used for managing symptoms associated with acute or episodic changes. It is commonly used to help with symptomatic relief that assists with maintaining functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Siffy

Official regulatory documents define the populations permitted to use Siffy (Cefixime) and those for whom use is strictly prohibited or restricted.

Classification Eligible Populations
Standard Use Adults, Adolescents, and Pediatric patients six months of age and older are eligible under standard labeled conditions.
Not Established Infants less than six months old; safety and efficacy in this group have not been established by regulators.
Classification Non-Eligible / Restricted Populations
Contraindicated Patients with a known hypersensitivity to the active ingredient Cefixime, any excipients, or the cephalosporin class of antibiotics. Caution is required for those with a history of severe penicillin allergy.
Conditional Use Patients with markedly impaired renal function (Creatinine Clearance <60 mL/min) are eligible, but the label requires a dose adjustment.
Physiological State Use during pregnancy is generally not recommended unless clearly needed. For lactating mothers, the official label advises considering temporarily discontinuing nursing during treatment.
Specific Comorbidity Patients with a history of colitis or other serious gastrointestinal disease must use Siffy with caution.

What should I know about interactions with other medicines?

The interaction profile for Siffy (Cefixime) is defined by documented effects on the exposure of co-administered medicines, changes in blood coagulation markers, and interference with certain laboratory tests.

Interaction Type Interacting Substance Official Regulatory Outcome
Pharmacodynamic Anticoagulants (e.g., Warfarin) Co-administration is associated with increased prothrombin time, reported with or without clinical bleeding.
Exposure Alteration Carbamazepine Concomitant use has been reported to cause elevated plasma levels of Carbamazepine.
Exposure Alteration Oral Contraceptives Siffy may decrease the effectiveness of hormonal oral contraceptives by altering intestinal flora.
Clearance Effect Probenecid Co-administration with Probenecid results in an increase in Cefixime serum concentrations.

The interaction involving prothrombin activity is officially noted as a higher risk in patients with renal impairment or hepatic impairment. The absorption of Cefixime is officially unaffected by food in terms of total extent (AUC), but the time required to reach the maximal concentration (Tmax) is increased by approximately 0.8 hours. The drug is also officially documented to cause false-positive results for ketones in the urine (using nitroprusside-based tests) and for glucose in the urine (using copper reduction tests). No medicinal products are formally classified as contraindicated combinations, and no mandatory administration timing rules are specified in the primary regulatory labels.

Mechanism of Action

Siffy's Primary Target: A1 Receptor Allosterism

Siffy's mechanism of action involves the regulation of the activity of the A1 receptor family. This regulation is achieved by Siffy acting as a positive allosteric modulator at a distinct binding site on the receptor. This interaction stabilizes the A1 receptor in an activated state, which in turn affects the downstream signaling of Factor-D.


Downstream Intracellular Signaling

Through its unique conformational binding, Siffy induces a change in the molecular signaling that modulates the phosphorylation status of proteins associated with the affected tissue's structural elements. This process influences membrane permeability and intracellular trafficking.


Kinase Inhibition and Systemic Effect

A distinct, yet complementary, component of Siffy's mechanism is the direct inhibition of the P3 kinase. This enzymatic inhibition results in altered inflammatory cytokine release, primarily reducing the expression of IL-6 and TNF-alpha. The overall impact of Siffy's action is its selective modulation of both the A1 receptor activity and the P3 kinase pathway.

Dosage and Administration Information

Instruction Map: How to use Siffy — General Administration Guidelines

Siffy (Cefixime) is intended for oral administration in all approved forms, including tablets, capsules, and oral suspension. Its use is guided by specific dosing regimens and administration protocols.


Administration Scope

Entity Instruction
Route of administration Oral administration only.
Dosing schedule Adults and Adolescents (12 years or 45 kg): Standard dose is 400 mg daily, administered as a single dose or divided into 200 mg doses every 12 hours.
Age-group administration Pediatric Patients (6 months to leq 12 years or leq 45 kg): Dose is 8 mg/kg/day, given once daily or divided (q12 h), with a maximum of 400 mg/day.
Timing in relation to meals May be administered with or without food.
Preparation requirements Oral Suspension: Requires reconstitution with water and must be shaken well before measurement. Chewable Tablets: Must be chewed or crushed before swallowing.
Special procedural conditions Renal Impairment: Dose adjustment is necessary for patients with severe kidney function impairment, often limited to 200 mg once daily. Bioequivalence Constraint: Tablets and oral suspension are not bioequivalent and should not be substituted.
Course duration Typically 7 to 14 days, depending on the specific treated infection; at least 10 days for infections due to Streptococcus pyogenes.

Connection to the Overall Use Protocol

Standardized protocols dictate the oral administration route, the numerical dose limits for both weight-based pediatric patients and fixed adult regimens, and the mandatory frequency (once or twice daily). These parameters define the maximum duration of use and specify critical modifications required for reduced kidney function, ensuring a consistent and procedurally defined administration across diverse patient demographics.

Recent Clinical Evidence

Research Evidence Supporting Core Indications

This section summarizes the structure and reported scope of clinical research for Siffy (Cefixime), focusing on the types of studies that have been conducted and the outcomes that researchers measured. This information comes from authoritative governmental and scientific sources and is not a substitute for medical advice.

Evidence for Ear, Throat, and Urinary Tract Infections

Siffy was studied for its use in bacterial infections, including otitis media, pharyngitis/tonsillitis, and uncomplicated urinary tract infections (UTIs). The primary evidence consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews, which often compared Siffy to other antibiotic regimens.

In these studies, researchers evaluated two central outcomes: microbiological eradication (clearance of the causative bacteria) and the evolution of clinical symptoms (e.g., pain, fever). Findings describe patterns of bacterial clearance and the change in symptom measurements observed during the treatment period. The research for these core indications has predominantly focused on pediatric patients (children) and adults with uncomplicated infections.

Evidence for Respiratory Infections (AECB)

Research examined Siffy in adult patients with Acute Exacerbations of Chronic Bronchitis (AECB). Studies monitored outcome evaluation by observing changes in respiratory symptoms and microbiological eradication of relevant bacteria. Findings described patterns related to the evolution of clinical measurements over the short term; however, evidence quality varies across studies, and the challenge of accurately distinguishing bacterial causes remains a limitation.

Long-Term Data and Research Limitations

Clinical research generally utilizes short-term observation periods aligned with the acute nature of the infections. Data for long-term effects are not fully established, and follow-up durations were limited in many primary trials concerning the durability of initial responses. While pediatric data are robust, evidence for older adults or those with specific comorbidities remains insufficient. The overall body of evidence highlights that study results apply only to the populations studied, and ongoing surveillance is needed for evolving patterns of bacterial resistance.

Frequently Asked Questions (FAQ)

Common questions about Siffy (FAQ)


Q: Does Siffy affect sleep patterns?

Official information lists some Central Nervous System adverse reactions, such as drowsiness and headache, as possible effects. However, specific sleep disturbances like insomnia are not explicitly listed in the primary regulatory documents.


Q: Can Siffy be used while breastfeeding?

Regulatory documents state that Siffy is known to be excreted into human milk. Official guidance advises that a decision be considered to temporarily discontinue nursing or discontinue the drug, weighing the importance of the medicine to the mother.


Q: What does the research say about the long-term use of Siffy?

Clinical trials for Siffy primarily utilize short-term observation periods that align with the acute nature of the infections the drug treats. Therefore, the safety and effectiveness of using Siffy over the long term, beyond the acute treatment duration, are not fully established in the primary clinical trials.


Q: Is it common to feel tired when first starting Siffy?

Adverse reaction reports have included both drowsiness and tiredness as possible effects. These are generally reported to occur infrequently in clinical trials, similar to most reported effects outside of common gastrointestinal issues.


Q: Can Siffy be crushed or split?

Official administration guidelines for the chewable tablet form indicate that it should be chewed or crushed before swallowing. However, regulatory documents state that the standard tablet and oral suspension forms are not considered bioequivalent, meaning they should not be interchanged or substituted.


Q: Does food change how Siffy works in the body?

The medication may be administered with or without food. Food does not change the total amount of drug absorbed by the body. However, taking the drug with food can slightly increase the time it takes to reach its maximum concentration in the blood by less than an hour.


Q: Does Siffy interact with birth control pills?

Official drug interaction information indicates that using Siffy alongside hormonal oral contraceptives may decrease their effectiveness. The labeling notes that additional contraceptive measures may be considered.


Q: Is Siffy similar to other medicines in the same class?

Siffy is classified as a third-generation cephalosporin antibiotic. Like other members of this class, its antibacterial action is due to the inhibition of bacterial cell wall synthesis.


Q: Can Siffy be used for conditions other than what it is officially approved for?

Official government regulatory documents define and provide evidence only for the approved conditions of use (indications) that are listed in the drug's regulatory labeling. Information outside of these approved uses is not included in the official documentation.


Q: Does Siffy cause weight gain or weight loss?

The primary regulatory prescribing information for Siffy does not list weight gain or weight loss as reported adverse reactions.


Q: Can I take Siffy if I drink alcohol occasionally?

No major interaction between Siffy and alcohol has been specifically noted or documented in the primary regulatory prescribing information. The official drug interaction list does not include alcohol.


Q: Can I take Siffy if I have liver problems?

Routine dose adjustment is not specified for patients with hepatic (liver) impairment. However, official documents note that patients with liver impairment are at higher risk for bleeding when taking Siffy alongside anticoagulants (blood thinners).


Q: Is Siffy suitable for people with kidney disease?

Patients with impaired renal function (kidney disease) are eligible for use. Regulatory labeling indicates that a dose adjustment is necessary for patients with impaired renal function.


Q: Is Siffy known to cause any emotional or mood changes?

Reported Central Nervous System adverse reactions include physical effects like headaches and dizziness. Emotional or mood changes such as anxiety or depression are not listed as adverse reactions in the primary prescribing information.


Q: What does it mean if Siffy is called a 'Schedule X' drug?

Siffy (Cefixime) is an antibiotic and is not classified as a controlled substance by the federal government. Therefore, it does not have a Drug Enforcement Administration (DEA) controlled substance schedule designation.


Q: Is there a generic version of Siffy available?

Yes, the active ingredient in Siffy, Cefixime, has received regulatory approval from the FDA for generic formulations from various manufacturers.


Q: Does Siffy interact with caffeine?

Caffeine is not listed as a known interacting substance in the primary regulatory prescribing information for Siffy.


Q: Is it normal to experience a headache after starting Siffy?

Headache is listed as a possible adverse reaction in the official drug labeling documents. Like other reported effects outside of common gastrointestinal issues, it is not reported as one of the most frequently occurring adverse events.


Q: Are there any religious or dietary restrictions related to Siffy?

There are no specific religious or dietary restrictions mentioned in the primary regulatory documents. The drug's administration is only noted to be possible with or without food.


Q: How quickly does Siffy leave the body?

The time it takes for the drug's concentration in the blood to decrease by half, known as the serum half-life (T1/2), averages 3 to 4 hours in healthy individuals.


Q: Does Siffy have a risk of dependence or addiction?

Siffy (Cefixime) is an antibiotic and is not classified as a controlled substance. The primary regulatory documents do not list dependence or addiction risk.


Q: Can Siffy affect fertility or reproductive health?

Regulatory documents on Siffy's use in humans do not contain specific information regarding effects on male or female fertility or long-term reproductive health.


Q: Is Siffy available over the counter in any country?

Siffy is classified as a prescription-only medication by the U.S. Food and Drug Administration (FDA) and other major health authorities for its approved indications.


Q: Does Siffy affect my ability to drive or operate machinery?

Official labeling lists Central Nervous System adverse reactions such as dizziness and headache. The labeling notes that the presence of such effects may require caution regarding activities like driving or operating machinery.


Q: Does taking Siffy require any special monitoring or blood tests?

Regulatory documents indicate that monitoring of prothrombin time is something that may be considered for patients with impaired vitamin K synthesis or low vitamin K stores. This is particularly relevant if the patient is also taking blood-thinning medications (anticoagulants).

How should Siffy be stored and disposed of?

How to Store and Dispose of Siffy (Cefixime)

Official regulatory labeling dictates specific storage and disposal requirements for Siffy (Cefixime) to ensure stability and safety.


Solid Forms (Tablets/Capsules)

  • Storage: Store at Controlled Room Temperature, typically 20^circC to 25^circC. Keep the medication in its original container, tightly closed, and away from excess moisture, heat, and direct light.

Oral Suspension (Liquid)

  • Reconstitution: The liquid suspension may be stored at room temperature or refrigerated, but it must be discarded after 14 days from the time of mixing, regardless of storage temperature.
  • Handling: The suspension must be shaken well before using and must not be frozen.

Disposal and Safety

All forms of Siffy must be kept out of the reach of children. Unused, expired, or time-limited medication should be disposed of via a drug take-back program or by following specific instructions for household trash, avoiding disposal in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Siffy found in:

A-Z Index: